We use cookies on our website. Carry on browsing if you’re happy with this or find out more

News

:

Kymab and Heptares seek cancer therapeutics

Protein Lab02 Pipette Syringe

Partnership with Heptares will develop antibodies that target GPCR proteins acting as checkpoints in cancer development.

Kymab has announced a strategic collaboration with Heptares Therapeutics to discover, develop and commercialise novel antibody therapeutics targeting a number of G-protein-coupled receptors (GPCR) with an initial focus on immuno-oncology.

GPCRs are widely expressed on cells of the innate and adaptive immune system and play key roles in modulating cell migration and recruitment to the tumour environment, activation, survival, proliferation and differentiation. GPCRs act at critical checkpoints that can be targeted by novel immunotherapy antibodies.

"GPCRs have long been intractable targets for antibody discovery resulting in dearth of products," said Dr Malcolm Weir, Chairman and CEO of Heptares, "We believe that our proven StaR technology can unlock this substantial opportunity, not just in immuno-oncology but also across other therapeutic areas where GPCR-targeted biologics could have a significant impact. By entering into strategic collaborations with companies with world-leading antibody discovery technologies, such as Kymab, we have the potential to discover, develop and commercialise a highly valuable pipeline of new biologic products."

Immuno-oncology is an exciting new area in the treatment of cancer where the body's immune system is activated to produce an immune response targeted at tumour cells. Immunotherapy drugs are poised to revolutionise the way cancer is treated and a number of immunotherapy antibody treatments have recently been approved.

"Antibodies are important therapeutic agents for cancer and other indications," said Dr David Chiswell, Chairman and CEO of Kymab. "Our collaboration with Heptares will allow us to combine stable antigens based on multiple GPCR targets with our world class Kymouse platform which has unparalleled diversity and will therefore rapidly identify and yield highly selective potent human monoclonal antibodies for unmet medical needs."

Under the agreement, Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), will apply its StaR® platform to create stable antigens based on multiple GPCR targets chosen by the companies. Kymab will then use its Kymouse™ human antibody discovery platform to generate antibodies in response to immunisation with these antigens. The Kymouse™ platform will assure the highest probability of finding the best-in-class antibodies with highly attractive drug properties.

Promising leads will be progressed using the partners' complementary skills, resources and development capabilities in order to bring innovative products into the clinic. Under the agreement, the companies will jointly conduct and share the costs of each antibody discovery and development programme.


Notes to Editors

Kymab, Kymouse, are trademarks of Kymab Limited.

About Heptares Therapeutics

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Kymab, MedImmune, MorphoSys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit Heptares website or Sosei website.

Find out which events we'll be attending this year

View events